Vanguard Group’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$161M Buy
7,341,356
+278,042
+4% +$5.02M ﹤0.01% 1655
2025
Q3
$85.7M Sell
7,063,314
-306,516
-4% -$4.15M ﹤0.01% 1924
2025
Q2
$137M Buy
7,369,830
+77,661
+1% +$1.54M ﹤0.01% 1693
2025
Q1
$140M Sell
7,292,169
-147,836
-2% -$4.33M ﹤0.01% 1641
2024
Q4
$268M Buy
7,440,005
+77,451
+1% +$2.62M ﹤0.01% 1399
2024
Q3
$312M Sell
7,362,554
-15,448
-0.2% -$655K 0.01% 1306
2024
Q2
$297M Buy
7,378,002
+325,432
+5% +$13.6M 0.01% 1265
2024
Q1
$250M Buy
7,052,570
+30,664
+0.4% +$822K ﹤0.01% 1378
2023
Q4
$208M Buy
7,021,906
+18,571
+0.3% +$385K ﹤0.01% 1488
2023
Q3
$145M Sell
7,003,335
-9,568
-0.1% -$263K ﹤0.01% 1597
2023
Q2
$172M Sell
7,012,903
-34,574
-0.5% -$1.11M ﹤0.01% 1545
2023
Q1
$286M Buy
7,047,477
+920,248
+15% +$38.1M 0.01% 1246
2022
Q4
$275M Sell
6,127,229
-67,047
-1% -$3.04M 0.01% 1242
2022
Q3
$296M Sell
6,194,276
-179,317
-3% -$9.83M 0.01% 1142
2022
Q2
$377M Buy
6,373,593
+66,869
+1% +$5.49M 0.01% 1031
2022
Q1
$733M Buy
6,306,724
+146,577
+2% +$17.1M 0.02% 745
2021
Q4
$927M Buy
6,160,147
+109,088
+2% +$14.7M 0.02% 685
2021
Q3
$722M Buy
6,051,059
+446,554
+8% +$49.2M 0.02% 774
2021
Q2
$546M Buy
5,604,505
+144,143
+3% +$12.9M 0.01% 942
2021
Q1
$482M Buy
5,460,362
+192,974
+4% +$17.9M 0.01% 979
2020
Q4
$504M Buy
5,267,388
+193,793
+4% +$20M 0.01% 875
2020
Q3
$576M Sell
5,073,595
-101,061
-2% -$10.6M 0.02% 716
2020
Q2
$512M Sell
5,174,656
-118,670
-2% -$9.47M 0.02% 754
2020
Q1
$341M Sell
5,293,326
-192,106
-4% -$13.5M 0.01% 842
2019
Q4
$327M Buy
5,485,432
+25,884
+0.5% +$1.6M 0.01% 1078
2019
Q3
$322M Sell
5,459,548
-767,532
-12% -$49M 0.01% 1033
2019
Q2
$402M Buy
6,227,080
+316,123
+5% +$20.4M 0.02% 907
2019
Q1
$375M Buy
5,910,957
+247,975
+4% +$13M 0.01% 937
2018
Q4
$215M Buy
5,662,982
+1,870,320
+49% +$66M 0.01% 1203
2018
Q3
$162M Buy
3,792,662
+1,884,560
+99% +$65.8M 0.01% 1531
2018
Q2
$42M Buy
1,908,102
+527,360
+38% +$6.48M ﹤0.01% 2214
2018
Q1
$6.85M Buy
1,380,742
+1,274,255
+1,197% +$4.11M ﹤0.01% 3010
2017
Q4
$251K Sell
106,487
-33,818
-24% -$106K ﹤0.01% 3892
2017
Q3
$1.02M Buy
140,305
+16,944
+14% +$107K ﹤0.01% 3586
2017
Q2
$987K Buy
123,361
+3,299
+3% +$30.5K ﹤0.01% 3570
2017
Q1
$1.44M Buy
120,062
+77,348
+181% +$1.69M ﹤0.01% 3478
2016
Q4
$919K Sell
42,714
-31,982
-43% -$1.23M ﹤0.01% 3584
2016
Q3
$5.72M Buy
74,696
+808
+1% +$58.9K ﹤0.01% 2940
2016
Q2
$5.57M Buy
73,888
+5,571
+8% +$448K ﹤0.01% 2922
2016
Q1
$5.95M Buy
68,317
+3,898
+6% +$341K ﹤0.01% 2874
2015
Q4
$7.61M Buy
64,419
+6,715
+12% +$666K ﹤0.01% 2782
2015
Q3
$5.08M Buy
57,704
+7,297
+14% +$849K ﹤0.01% 2962
2015
Q2
$5.46M Buy
50,407
+3,685
+8% +$458K ﹤0.01% 2976
2015
Q1
$5.9M Buy
46,722
+16,148
+53% +$2.1M ﹤0.01% 2914
2014
Q4
$3.88M Buy
30,574
+1,568
+5% +$217K ﹤0.01% 3022
2014
Q3
$3.89M Buy
29,006
+8,217
+40% +$1.15M ﹤0.01% 2970
2014
Q2
$3.38M Buy
20,789
+12,704
+157% +$2.16M ﹤0.01% 3027
2014
Q1
$1.79M Buy
8,085
+23
+0.3% +$5.87K ﹤0.01% 3273
2013
Q4
$2.08M Buy
+8,062
New +$1.84M ﹤0.01% 3170

Other funds holding TNDM

Vanguard Group's TNDM Position: Q4 2025 in Review

Vanguard Group increased its Tandem Diabetes Care (TNDM) stake by 3.9% in Q4 2025, buying an estimated $5.02M and bringing the position to 7,341,356 shares worth $161M. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Vanguard Group first reported a position in TNDM in Q4 2013 and has held it in 49 quarters since. The position peaked at $927M in Q4 2021. 268 funds tracked by Wall St. Rank hold TNDM as of Q4 2025.

  • Vanguard Group held 7,341,356 shares of Tandem Diabetes Care worth $161M as of Q4 2025.
  • Vanguard Group bought 278,042 Tandem Diabetes Care shares in Q4 2025, an estimated $5.02M.
  • Tandem Diabetes Care made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1655 holding.
  • Vanguard Group first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 49 quarters since.
  • Vanguard Group's Tandem Diabetes Care position peaked at $927M in Q4 2021.
  • 268 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.